BIOMAT Database Logo BIOMAT Database Logo

Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma. 1988

W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario.

A total of 342 eligible, previously untreated patients with Stage III or IV epithelial ovarian carcinoma were treated with Adriamycin and cisplatin, both at 50 mg/m2, for nine courses. Of the 210 patients who had clinically detectable disease after initial surgery, 85 (41%) had a complete clinical response and 45 (21%) had a partial clinical response. A total of 197 were clinically free of disease at the completion of chemotherapy and 175 of these had a second-look laparotomy; 55 had no macroscopic or microscopic evidence of residual disease after multiple random biopsies were examined histologically (complete surgical/histologic response). The major determinants of complete surgical/histologic response were diameter of largest residual tumor prior to treatment, ECOG performance status, and grade, patients with grade 3 tumors having a higher complete response rate than those with grade 1 or 2 tumors. The major determinants of survival were ECOG performance status and diameter of largest residual tumor prior to treatment. Median survival of the total group was 1.8 years.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.
October 1988, Tumori,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
Role of intervention surgery in stage III-IV epithelial ovarian carcinoma.
January 1985, Progress in clinical and biological research,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
April 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma.
February 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
July 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
[Chemotherapy of stage III and IV ovarian carcinoma].
September 1980, Nederlands tijdschrift voor geneeskunde,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
[Stage III and IV epithelial ovarian cancers. Therapeutic problems].
January 1992, Revue francaise de gynecologie et d'obstetrique,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma.
August 1994, Gynecologic oncology,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
[A combination of cyclophosphamide, adriamycin and platinum (CAP) in the treatment of stage III and IV ovarian cancer].
January 1988, Jugoslavenska ginekologija i perinatologija,
W E Shelley, and J C Carmichael, and L B Brown, and R C Fraser, and M E Kirk, and G V Krepart, and M Levitt, and M Roy, and A R Willan, and K S Wilson
Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
February 1979, Cancer treatment reports,
Copied contents to your clipboard!